Reversible posterior leukoencephalopathy syndrome (RPLS) is uncommon neurological syndrome that is characterized by specific clinical and radiologic findings. Previous reported associations of RPLS include hypertension, eclampsia, renal impairment and drugs. Prompt diagnosis and therapy is critical to ensure resolution of the neurological disability. Some cases have been reported in association with the increased use of antineoplastic agents in cancer patients. We report the case of a 62-year-old man who was diagnosed with RPLS after receiving carboplatin and paclitaxel chemotherapy for lung cancer. This case appears to be the first recognized association of RPLS with this regimen.
Introduction
Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinicoradiologic syndrome that is characterized by headache, altered alertness and behavior ranging from drowsiness to stupor, seizures, vomiting, mental abnormalities including confusion and diminished spontaneity and speech, and abnormalities of visual perception (1) . MRI reveals characteristic white matter changes indicative of cerebral edema. The underlying pathophysiologic mechanism is proposed to be one of vasogenic edema without infarction (1) (2) (3) (4) . Recently, some cases have been reported in association with the increased use of cytotoxic and molecular target agents in cancer patients, and relevant reports have increased with advances in radiological examinations. Here, we report a case of this rare disease in a lung cancer patient who was undergoing carboplatin and paclitaxel chemotherapy.
Case Report
A 62-year-old man with a past smoking history and without a previous medical history was diagnosed with nonsmall cell lung cancer ( Fig. 1 ) in September 2010. Metastases were not found on radiological examination at that time. The diagnosis was squamous cell lung cancer in the right upper lobe, cT2aN2M0, StageIIIA. He was started on chemotherapy with carboplatin (AUC 6 min·mg/mL) and paclitaxel (200 mg/m 2 ) on day one by intravenous administration every three weeks prior to intended sequential chemoradiation. Granulocyte-colony stimulating factor (G-CSF) was not prescribed and 6 mg of intravenous dexamethasone was administered on day one as antiemetic medication during chemotherapy. A baseline cranial MRI was taken, and there were no brain metastatic findings.
He presented to the emergency department on day 22 post-course three with heaviness of the head and ptosis of the right mouth angle and reported a temperature of 37.7 Table 1 . Laboratory Findings on Admission bin of 7.3 g/dL, platelets of 9.8×10 4 /μL and a white cell count of 6,400/μL. Vital signs recorded on admission showed a heart rate of 89 beats per minute, blood pressure 150/94 mmHg and a temperature of 37.6 . Initially we considered the possible causes of heaviness of the head and ptosis of the right mouth angle to include: 1) brain infarction, 2) cerebral apoplexy, and 3) brain metastases. Gadolinium enhanced MRI scan of brain was performed within 24 hours ( Fig. 2 ) and a lumbar puncture was performed. T2 and fluid attenuation inversion recovery (FLAIR) MRI showed subcortical white matter hyperintense signals in the frontal lobe which were of low-intensity areas in T1 sequences, but not really consistent with metastasis. The major venous sinuses and deep and large cortical veins were patent on conventional MRI. Laboratory examination and cerebrospinal fluid examination revealed no abnormalities other than anemia (Table 1) . He was treated with supportive therapy that included monitoring of his blood pressure and prevention of brain edema with glycerol and betamethasone, despite an evolving anemia. A few days after the occurrence of heaviness of the head and ptosis of the mouth corner, his condition gradually improved so did not the heaviness of his head, although the ptosis of the mouth remained. Two weeks after the occurrence of ptosis of the mouth, his facial nerve palsy was nearly intact. Two weeks later, a follow-up MRI scan showed slight improvement of the frontal lobe ( Fig. 3 ), though the high intensity signal remained bilaterally. Furthermore, a follow-up MRI at one month after the initial episode showed that the abnormal signal had improved significantly ( Fig. 4) . No further seizure activity ensued and all focal neurological findings were resolved. Based on the clinical and radiologic findings, a reversible posterior leukoencephalopathy syndrome (RPLS) was diagnosed. The patient was discharged from our hospital and treated as an outpatient. Three months after discharge, the patient started radiation therapy. All focal neurological findings were completely resolved and a follow-up MRI showed complete resolution of the abnormalities.
Discussion
The first case of RPLS was reported by Hinchey et al (1) in 1996 as a condition characterized by reversible neurological and radiological findings. In this series, the clinical characteristics most commonly seen are abrupt increase in blood pressure, seizures, either generalized or focal, and visual disturbance. Other manifestations include paresis, headache, altered mental status, nausea, vomiting and stupor. RPLS is typically seen in patients with hypertensive encephalopathy, eclampsia, renal disease, and the use of immunosuppressive agents. There are no diagnostic criteria or specific clinical findings for RPLS, and several disease entities must be included in its differential diagnosis, including infection, stroke, toxic, venous thrombosis, metabolic encephalopathy, demyelinating disorders and vasculitis (Table 2) (4, 5). The syndrome is characterized by its reversibility on control of hypertension and other primary instigating factors.
The present case had no obvious risk factor for RPLS (Table 3 ) (5-10), and it is reasonable to interrelate the clinical symptoms and signs, radiologic findings (before and after the event), and the administration of carboplatin and paclitaxel combination chemotherapy with a diagnosis of RPLS. While chemotherapy in this case included low-dose dexamethasone as an antiemetic agent, administration of the agent was terminated some 22 days prior to the onset of manifestations. Although high-dose dexamethasone has been associated with RPLS (11), this time interval and dosage make an association in this case less likely.
Though the pathophysiology of RPLS remains poorly understood, the key mechanism is thought to be cerebral vasogenic edema precipitated by acute elevation in systolic pressure and failure of vascular autoregulation. The breakdown of the blood-brain barrier leads to extravasation of fluid and occasionally blood products into the brain parenchyma (12) . Toxic damage to the vascular endothelium caused by immunosuppressive agents and cytotoxic agents is further postulated to contribute to the pathophysiological features of RPLS (1, 13) . In the present case, carboplatin and paclitaxel regimen will be associated with toxic damage to the vascular endothelium.
Increasing numbers of antineoplastic therapies used in hemato-oncology have been reported as a cause of RPLS since it was first described in 1996 (1) . These therapies include the platinum analogues (e.g. cisplatin, carboplatin and oxaliplatin), antimetabolites (e.g. gemcitabine), folate antagonists, anthracyclines, and the vinca alkaloids (Table 3 ). Platinum analogues are common chemotherapeutic agents used for solid and hematologic malignancies, and central nervous system (CNS) toxicity secondary to platinum therapy has been well reported, and the first association with RPLS emerged in 1980 (14, 15) . It appears to be associated with high-dose cisplatin therapy and usually occurs after cumulative doses of at least 200 mg/m 2 (16, 17) . Although there have been numerous previous reports of cisplatinrelated RPLS in the literature, this complication has rarely been described in association with carboplatin (7, 17) . Furthermore, to the best of our knowledge, paclitaxel has been associated in only one report (18) , and our report is the first case of RPLS after carboplatin and paclitaxel regimen.
MRI is the favored modality of investigation for RPLS. MRI findings are often characteristic and represent an essential component of the diagnosis (5) . MRI findings typically show symmetrically distributed areas of white matter edema in the posterior cerebral hemispheres, especially in the parietal-occipital region. The radiographic lesion of the present case located in frontal lobe is an atypical location. The most commonly involved location is the parietooccipital brain region, which was seen in 108 (94%) of the 115 cases. This was followed by the frontal lobe in 88 cases (77%), the temporal lobe in 74 (64%), the cerebellum in 61 (53%), the basal ganglia in 39 (34%), and the brainstem in 31 (27%) (19) . Despite the syndrome's name, radiographic lesions in RPLS are rarely isolated to the 'posterior' parietooccipital white matter and instead often involve the cortex, frontal lobes, basal ganglia, and brainstem, as in the present case (20, 21) . Bartynski et al reported that atypical lesion locations were also identified with a greater than expected degree of frequency (20) . It must be remembered that, despite the term of 'posterior', RPLS is not always located in the posterior parieto-occipital white matter, as in the present case. In the majority of reported cases, RPLS is fully reversible within a period of days to weeks, and repeat MRI scans can show resolution of leukoencephalopathy, as in our case (22) .
The etiology of RPLS can be multifactorial, and because the clinical reports are limited to case reports or small series, it is difficult to establish recommendations for treatment. With prompt recognition and initiation of appropriate treatment, RPLS is usually reversible. This case was treated with supportive therapy that included control of blood pressure and the prevention of brain edema with glycerol and corticosteroids. In cases of RPLS associated with drugs, it is recommended that the offending agent be withdrawn (10) . The aim of treatment for RPLS is to lower blood pressure. Agents such nicardipine, labetalol, and nitroprusside can all be titrated to desirable doses to maintain adequate cerebral perfusion (22) . And the administration of corticosteroids might speed up recovery (14) .
In conclusion, we report an extremely rare case of RPLS detected by clinical imaging during carboplatin and paclitaxel combination chemotherapy. The timing of chemotherapy and the sequence and prompt improvement of MRI brain findings after withdrawal of the forementioned chemotherapy combination leads us to suggest this association. Although the combination chemotherapy of advanced nonsmall cell lung cancer with carboplatin and paclitaxel is a clinically important treatment modality, this drug combination has not been previously reported as a predisposing factor for RPLS. There are increasing numbers of antineoplastic agents reported to be associated with the development of RPLS, therefore all physicians must be aware of this syndrome.
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